Product information and disease descriptionPlace of product in therapyApproaches to treatment
Heterogeneity of treatment effect
13 evidence topics · 10 sources
HPV status: response at 1500 mg weekly in the phase 1b cohort
HPV status: progression-free and overall survival at 1500 mg weekly
HPV status at an earlier data cut of the same cohort
PD-L1 CPS 1-19 versus 20 or greater at 1500 mg weekly
Locoregional recurrence, tumor burden, and performance status at 1500 mg weekly
Confirmed response by CPS, tumor burden, and disease extent across the three dose cohorts
| Subgroup, % (n/N) | 750 mg weekly (n=30) | 1500 mg weekly (n=28) | 2000 mg every 2 weeks (n=27) |
|---|---|---|---|
| CPS 1-19 | “73 (8/11)” | “54 (7/13)” | “57 (8/14)” |
| CPS 20 or greater | “47 (9/19)” | “53 (8/15)” | “38 (5/13)” |
| Sum of target lesion diameters 50 mm or less | “55 (11/20)” | “53 (8/15)” | “53 (9/17)” |
| Sum of target lesion diameters greater than 50 mm | “60 (6/10)” | “54 (7/13)” | “40 (4/10)” |
| Sum of target lesion diameters greater than 70 mm | “50 (2/4)” | “43 (3/7)” | “33 (2/6)” |
| Locoregional disease only | “38 (6/16)” | “62 (5/8)” | “50 (7/14)” |
| Distant metastatic disease only | “100 (5/5)” | “29 (2/7)” | “40 (2/5)” |
| Locoregional and distant metastatic disease | “67 (6/9)” | “62 (8/13)” | “50 (4/8)” |
Dose cohort: response depth and progression-free survival
| Dose cohort | Confirmed ORR (95% CI) | Complete response | Responders with deep response | Median PFS (95% CI), months |
|---|---|---|---|---|
| 750 mg weekly | “57% (37%-74%)” | “13%” | “47% (8/17)” | “6.9 (4.6-NE)” |
| 1500 mg weekly | “54% (34%-72%)” | “25%” | “80% (12/15)” | “9.9 (4.4-22.7)” |
| 2000 mg every 2 weeks | “48% (29%-68%)” | “30%” | “77% (10/13)” | “12.7 (4.9-NE)” |
Dose cohort: 1500 mg versus 750 mg weekly at the December 2025 data cut
Pembrolizumab monotherapy in KEYNOTE-048 by PD-L1 CPS
“The median OS was 14.9 months (95% CI, 11.5 to 20.6) for pembrolizumab alone versus 10.8 months (95% CI, 8.8 to 12.8) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population (HR, 0.61; 95% CI, 0.46 to 0.81; nominal one-sided P = .00034), 12.3 months (95% CI, 10.8 to 14.8) versus 10.4 months (95% CI, 9.0 to 11.7) in the CPS ≥ 1 population (HR, 0.74; 95% CI, 0.61 to 0.89; nominal one-sided P = .00080), and 11.5 months (95% CI, 10.3 to 13.5) versus 10.7 months (95% CI, 9.3 to 12.1) in the total population (HR, 0.81; 95% CI, 0.68 to 0.97; nominal one-sided P = .00994” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The ORR was 23.3% (11 CR/20 PR) for pembrolizumab alone versus 36.1% (4 CR/40 PR) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population, 19.1% (15 CR/34 PR) versus 34.9% (7 CR/82 PR) in the CPS ≥ 1 population, and 16.9% (15 CR/36 PR) versus 36.0% (8 CR/100 PR) in the total population” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pembrolizumab in KEYNOTE-048: CPS 1-19 and CPS less than 1 subgroups
“For pembrolizumab versus cetuximab-chemotherapy, the median overall survival was 7.9 versus 11.3 months in the PD-L1 CPS < 1 subgroup (hazard ratio [HR], 1.51 [95% CI, 0.96 to 2.37]) and 10.8 versus 10.1 months in the CPS 1-19 subgroup (HR, 0.86 [95% CI, 0.66 to 1.12]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Increased efficacy of pembrolizumab or pembrolizumab-chemotherapy was observed with increasing PD-L1 expression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pembrolizumab in KEYNOTE-048: other subgroups and HPV status
“In subgroup analyses, HRs generally favored pembrolizumab alone except for recurrent-only disease (locally recurrent disease and disease that spread to cervical lymph nodes” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“including in patients with poor prognostic markers such as smoking history and HPV-negative oropharyngeal cancer.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Real-world first-line pembrolizumab by HPV status and primary site
“Among those receiving pembrolizumab monotherapy, the median rwOS was 20 months for those with HPV-positive tumors versus 9 months for those with HPV-negative tumors; 17 months for those with an ECOG PS of 0–1 versus 6 months for those with an ECOG PS of 2–4; and 13 months for those with oropharyngeal tumors versus 9 months for those with tumors of the larynx, 5 months for those with oral cavity tumors, and 6 months for individuals with tumors of the hypopharynx” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among individuals receiving pembrolizumab plus chemotherapy, the median rwOS was 15 months for those with HPV-positive tumors versus 7 months for those with HPV-negative tumors” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote